Abstract
SummarySummaryNovelty: A novel group of compounds which sensitize multidrug resistant (MDR) cancer cells to chemotherapy is disclosed. In contrast to similar known agents, the claimed compounds are non-toxic at their effective dose levels.Biology: The efficacy of compounds as inhibitors of MDR is evaluated in the CHO cell line CHRC5, treated with doxorubicin (5 mg/ml). EC50 data (0.018 − 0.72 mM) refer to cell viability relative to doxorubicin-treated controls. The EC50 for the known agent verapamil was 3mM. Oral toxicity in mice is said to be negligible at 300mg/kg.Chemistry: Procedures are outlined for the synthesis of one hundred and thirty-seven named examples of which thirty-six are specifically claimed, including 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-diethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridinecarboxamide. Thirteen novel compounds are amongst 101 named intermediates.Structure:
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
